Screening means testing for a disease before you have symptoms. That single distinction
explains most of the confusion around health checks — and most of the disappointment people
feel when a test does not deliver what they expected.
This guide covers what screening is, what the evidence currently supports, where it genuinely
helps, where it causes harm, and what to ask before paying for a screening package. It is
information, not medical advice, and it is not a substitute for a conversation with a clinician
who knows your history.
Screening and diagnostic testing are not the same thing
They use similar machines and often the same lab, but they answer different questions.
- Screening asks: you feel fine — is there anything here we should look at?
It is applied to large groups of people who have no symptoms. - Diagnostic testing asks: you have a symptom or an abnormal result — what is
causing it? It is applied to one person with a specific question.
This matters for a practical reason. A screening test that returns something unexpected does not
give you a diagnosis. It gives you a reason to do a diagnostic test, which is why a positive screening result is not a diagnosis. The screening result is the
beginning of the process, not the end of it.
Why recommendations differ by age and risk
In the United States, the U.S. Preventive Services Task Force
(USPSTF) reviews the evidence for preventive services and assigns each one a grade. Those grades rest on evidence from clinical trials and other research studies.
Grade A and Grade B mean the Task Force found a high or moderate
net benefit — benefit after harms are subtracted.
Examples of current Grade A and B recommendations for adults:
- Colorectal cancer — screening for adults aged 50 to 75 (Grade A), and
aged 45 to 49 (Grade B). - Breast cancer — in April 2024 the USPSTF lowered the starting age,
recommending screening mammography every two years beginning at age 40. - Blood pressure — screening for adults aged 18 and over, with
measurements taken outside the clinical setting to confirm a diagnosis before treatment starts. - Hepatitis C — one-time screening for adults aged 18 to 79 (Grade B).
- HIV — routine screening for adolescents and adults (Grade A).
- Abdominal aortic aneurysm — one-time ultrasound for men aged 65 to 75
who have ever smoked (Grade B).
Notice the pattern. Every recommendation is bounded — by age, by sex, by smoking history,
by frequency. That is not bureaucratic caution. It is the evidence saying that the same test
produces a different balance of benefit and harm in different people.
The AAA recommendation is the clearest illustration: one ultrasound, for men in a ten-year age
window, who have smoked. Outside that group, the evidence does not support the same conclusion.
The part most screening marketing leaves out
Screening has real costs, and they are not only financial. Any honest account includes them.
False positives
A test says something is there when nothing is. What follows is a diagnostic work-up —
more tests, sometimes a biopsy, and a period of waiting that people consistently describe as
distressing. The anxiety is not a footnote; for many people it is the main harm they actually
experience.
False negatives
A test says nothing is there when something is. The risk here is a false sense of security
— a clear screening result is not a guarantee of health, and it is not a reason to ignore a
symptom that appears later.
Overdiagnosis
This one is the least intuitive and the most important. Overdiagnosis means correctly finding a
real abnormality that would never have caused symptoms or shortened your life. The finding is not
a mistake — it is genuinely there. But treating it delivers no benefit while carrying all the
usual risks of treatment. Because you cannot tell in advance which findings would have stayed
harmless, this is difficult to avoid rather than simply careless. The arithmetic behind this, and behind false positives generally, is covered in how to read a test result.
Incidental findings
Broad imaging often finds something unrelated to what was being looked for. Some of it matters.
Much of it does not, and sorting one from the other takes time, money and further testing.
Why “more testing” is not automatically better
It is intuitive to think that more information can only help. Screening is one of the places
where that intuition breaks down, because every test carries a probability of being wrong in both
directions, and because finding something is not the same as benefiting from finding it.
This is precisely why recommendations specify who should be screened and how often. A guideline
that says “adults aged 45 to 75” is not withholding a benefit from a 30-year-old. It reflects
evidence that in a 30-year-old, the same test would produce more harm than good.
Evaluating a private screening service
Private screening — often a bundle of ultrasound scans and blood tests offered directly to
consumers — is a legitimate industry. It is also one where the marketing usually foregrounds
benefit and says little about the harms above.
Questions worth asking before you pay — covered at greater length in our ten-question checklist for screening packages:
- Which of these tests is recommended for someone with my age and risk profile?
If a package contains ten tests and two are recommended for you, that is worth knowing before you
buy the package. - What happens if something is found? Does the service arrange follow-up, or
does the result arrive by post for you to take to a clinician? - Who interprets the results, and what are their qualifications?
- What is the false-positive rate for these specific tests? A service that
cannot answer this is worth a second look. - What is the total cost, including any follow-up? The advertised price is
often for the screening alone. - Will my regular clinician receive these results?
- Is this a subscription? Check the renewal terms before, not after.
A service that answers these plainly is behaving well. One that responds with urgency,
countdowns or claims that everybody should be tested is telling you something about its priorities.
When to talk to a clinician instead
Screening is for people without symptoms. If you have a symptom, you are not looking for
screening — you are looking for diagnosis, and a self-ordered screening panel is the
wrong tool. A persistent or worrying symptom warrants a clinician, not a test bundle.
A conversation is also the better starting point if you have a family history of a specific
condition, a chronic condition already under management, or if you simply are not sure which
recommendations apply to you. Risk-based screening decisions depend on details that a package
cannot know about you.
What to take from this
- Screening tests people without symptoms; diagnostic testing investigates a specific question.
- Recommendations are bounded by age and risk because the benefit–harm balance shifts
between groups. - USPSTF Grade A and B means high or moderate net benefit — benefit after harms.
- False positives, false negatives, overdiagnosis and incidental findings are ordinary outcomes,
not rare failures. - A normal result is reassurance, not a guarantee.
- Before buying a screening package, ask which tests actually apply to you and what happens next
if something is found. - Symptoms call for a clinician, not a screening panel.
Sources
- U.S. Preventive Services Task Force — A and B Recommendations
- USPSTF Recommendations for Physical Examination Procedures for Average Risk Asymptomatic Adults (NCBI Bookshelf)
MediVara publishes health journalism. This article is not medical advice and is not reviewed
by a licensed clinician. Screening decisions depend on your individual history and risk —
discuss them with a qualified healthcare professional.
Frequently asked questions
What is the difference between a screening test and a diagnostic test?
A screening test looks for evidence of disease in someone who has no symptoms. A diagnostic test is used when symptoms or an abnormal result are already present, to find out what is causing them. Screening tests are usually less invasive and carry little risk of complications; diagnostic tests, such as a biopsy, can be more invasive and carry a small risk. A positive screening result indicates increased risk, not a diagnosis.
At what age should I start screening?
It depends entirely on the test and on your risk factors. The USPSTF recommends colorectal cancer screening from age 45, breast cancer screening every two years from age 40, blood pressure screening from age 18, one-time hepatitis C screening for adults aged 18 to 79, and a one-time abdominal aortic aneurysm ultrasound for men aged 65 to 75 who have ever smoked. There is no single starting age for screening in general.
Does a normal screening result mean I am healthy?
No. A normal result is reassurance, not a guarantee. False negatives exist, and a clear result from a previous test does not answer a symptom that appears later. If you develop a symptom, that warrants attention regardless of past results.
Is more screening always better?
No, and this is the least intuitive part of screening. Every test has a chance of being wrong in both directions, and finding something is not the same as benefiting from finding it. Broader testing produces more false positives, more incidental findings and more overdiagnosis. This is why recommendations specify who should be screened rather than recommending everything for everyone.
Are recommended screenings covered by insurance in the US?
Under the Affordable Care Act, most non-grandfathered health plans must cover preventive services rated A or B by the USPSTF without cost sharing when delivered in network. Coverage rules can differ for a self-ordered screening or for follow-up diagnostic testing after an abnormal result, so it is worth confirming with your plan before assuming a cost is covered.
Leave a Reply